Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

In this study, the therapeutic response of topical minoxidil solution was not significantly enhanced by adding topical finasteride, questioning its additional value in treating male pattern androgenetic alopecia.

This study found that using hollow mesoporous silica nanoparticles as carriers in a topical finasteride formulation significantly enhanced drug retention and hair regrowth in an AGA mouse model, suggesting a promising approach for treating androgenetic alopecia with reduced side effects.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

Chitosan-decorated carriers may improve topical finasteride delivery for hair loss treatment.

This study described the development and evaluation of a finasteride nanogel for treating androgenetic alopecia, reporting higher cumulative drug release and enhanced spreadability compared to a plain gel, suggesting potential as a treatment option.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

Finasteride solution helps treat hair loss.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This study found that a lipid nanoemulsion-based gel of finasteride for topical use improved hair growth and was effective against alopecia, with slow skin permeation and increased efficacy compared to a testosterone-treated group.

This study developed and validated a precise and rapid HPLC method to simultaneously determine Minoxidil and Finasteride in pharmaceuticals, demonstrating successful application for routine quality control without interference from excipients.

In this study, researchers developed a novel gel formulation combining zinc oxide nanoparticles and finasteride-loaded nanostructured lipid carriers, which showed promising results for topical delivery and effective skin penetration, potentially offering a new treatment approach for androgenic alopecia.

This study found that both intradermal platelet-rich plasma and topical minoxidil with finasteride resulted in similar hair growth improvement in patients with androgenetic alopecia over 12 months.

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

This study evaluated Finasteride-loaded nanostructured lipid carriers for topical use in treating androgenetic alopecia and found that these carriers offer sustained drug release and may reduce systemic side effects compared to oral administration.

This study developed a peptide-based topical delivery system that enhanced hair growth with reduced systemic exposure to finasteride, showing efficacy comparable to 5% minoxidil in vivo while using significantly less finasteride than oral doses.

In this article, researchers explored the potential of lipidic nanocarriers to enhance the delivery and effectiveness of finasteride in a topical gel form for androgenic alopecia, aiming to improve treatment options and reduce systemic adverse effects.

This study found that liquid crystalline nanoparticles formulated with Cremophor surfactants significantly enhanced skin permeation of finasteride compared to lower surfactant concentrations.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This study found topical finasteride and minoxidil both improved hair loss clinically and trichoscopically more effectively than spironolactone in women with female pattern hair loss.

This study found that a combination of topical finasteride 0.25% with minoxidil 5% was more effective than using topical minoxidil 5% alone for treating male pattern androgenic alopecia over a 12-week period.

This study found that the combination of platelet-rich plasma with topical minoxidil and finasteride was more effective in treating androgenetic alopecia than the conventional minoxidil and finasteride therapy alone.